Forma’s Dinner Seminar – From Concept to Commercial: Solving Challenges in Modified Release Formulations

Speaker: Dr. Ruchit Trivedi, Executive VP of Operations, brings extensive industry experience from Lilly, Loxo Oncology, BioDuro, Banner, and Array Bio. He will be speaking on the topic below, followed by an interactive Q&A panel featuring industry leaders and a networking session.

• • Formulation design directly drives in vivo performance. Optimizing enteric trigger pH and release location had the greatest impact on bioavailability, while predictive in vitro dissolution testing effectively guided formulation selection.
  • Layered Multi-Unit Particulate Systems (MUPS) provide a scalable, commercially proven platform that co-localizes the peptide with permeation enhancers, reduces physiological variability, and enables precise control of release location.
  • Commercial success depends on designing for manufacturability from day one. Simple, scalable processes, proven excipients, robust supply chains, and early CMC integration are essential for successful technology transfer and commercialization.

Forma is a CDMO based in Irvine, CA specializing in oral solid dosage development and manufacturing, supporting programs from formulation through commercial supply, with particular depth in amorphous solid dispersions (SDD and HME) and modified release dosage forms. We have 27 GMP rooms and 5 R&D rooms in two facilities with a total of 100,000 sq ft footprint to serve your development needs. This session is a chance to see how those approaches play out on real programs and to connect with our team directly.